SEPNSepterna Inc. Common Stock
40.00USD-8.95%Mkt Cap: 1.87B $P/E: —3d ago
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap1.87B $
Enterprise Value1.55B $
Revenue (TTM)98.88M $
Gross Profit98.88M $
Net Income (TTM)-48.88M $
Revenue/Share2.213 USD
Last Price40.00 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees123
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-21.02
PEG—
EV/EBITDA-28.57
EV/Revenue15.72
P/S19.25
P/B4.84
EPS (TTM)-0.49
EPS (Forward)-1.94
52W Range
10.7473% of range51.09
52W High51.09 USD
52W Low10.74 USD
Profitability
Gross Margin100.00%
Oper. Margin-62.95%
EBITDA Margin-55.01%
Profit Margin-106.37%
ROE-12.80%
ROA-8.20%
Growth
Revenue Growth22375.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF110.19M $
CapEx (TTM)518.00K $
FCF Margin29.88%
FCF Yield1.58%
Net Debt-349.78M $
Net Debt/EBITDA6.43
Balance Sheet
Debt/Equity0.06
Current Ratio5.00
Quick Ratio4.89
Book Value/Sh8.426 USD
Cash/Share7.977 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)54.22 USD
Upside (mean)+35.6%
Target Range48.00 USD – 62.00 USD
$48.00+35.6% to mean$62.00
# Analysts9
Ownership
Shares Out.46.68M
Float26.41M
Insiders3.07%
Institutions98.64%
Short Interest
Short Ratio8.3d
Short % Float14.98%
Short % Out.7.68%
Shares Short3.51M
Short (prev mo.)3.15M
Technical
SMA 5036.66 (+9.1%)
SMA 20028.64 (+39.6%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)407.62K
Avg Vol (10d)608.76K
Technical Indicators
RSI (14)51.3
MACD2.1654
MACD Signal2.3981
MACD Hist.-0.2327
BB Upper49.42 USD
BB Middle39.95 USD
BB Lower30.47 USD
BB Width47.43%
ATR (14)2.590 USD
Vol Ratio (20d)0.69x